Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pubertal induction for bone health in children with neuromuscular disease
ACTRN12619001372178Phase 4Recruiting
- Sponsor
- Murdoch Children's Research Institute
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of AndroForte and estradiol in delayed puberty and low bone mineral density (2 arms), sponsored by Murdoch Children's Research Institute. Primary endpoint: Bone mineral density and bone mass. Started Sep 2018; status: recruiting.
02
Drugs
AndroForteestradiol
03
Conditions
delayed pubertylow bone mineral density
Beyond the preview
Go deeper on ACTRN12619001372178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001372178.